Table 1.
Characteristics of Subjects at ART Initiation.
| Median (interquartile range),
or % (no.) |
TDF-Treated (N = 44) |
Non-TDF-Treated (N = 43) |
P-value |
|---|---|---|---|
| Age | 34 (30,41) | 37 (30, 44) | 0.14 |
| Race (% white) | 41% (18) | 33% (14) | 0.42 |
| % Male | 75% (33) | 77% (33) | 0.85 |
| Weight (kg) | 74.4 (65.9, 81.1) | 74.8 (66.1, 88.6) | 0.55 |
| Nadir CD4 cell count (cells/mm3) | 91 (20, 232) | 236 (148, 334) | <0.01 |
| Baseline HIV-1 RNA (copies/mL) | 86,400 (45,316, 147,500) | 72,759 (21,575, 112,381) | 0.28 |
| Time since HIV diagnosis (months) | 17.5 (3, 66) | 12 (5, 36) | 0.65 |
| % Protease inhibitor use | 48% (21) | 26% (11) | 0.03 |
| % Lopinavir/ritonavir | 2% (1) | 9% (4) | 0.16 |
| % Atazanavir | 45% (20) | 14% (6) | <0.01 |
| % Fosamprenavir | 0% | 2% (1) | 0.31 |
| % Zidovudine | 0% | 91% (39) | |
| % Abacavir | 0% | 40% (17) | |
| % Current smokers | 71% (31) | 56% (24) | 0.16 |
| % Current alcohol use (>2 units/day) | 7% (3) | 12% (5) | 0.46 |
| 25 hydroxyvitamin D (ng/mL) | 22.6 (12.3,31.5) | 20.7 (13.4, 26.2) | 0.50 |
ART, antiretroviral therapy; TDF, tenofovir